Trial Profile
Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin; Cyclophosphamide; Paclitaxel
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms Triple-B
- 21 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 18 Oct 2021 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
- 14 Jun 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.